Luis Pinheiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luis Pinheiro has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Alexandra Pacurariu
Real World Evidence Workstream European Medicines Agency Amsterdam The Netherlands
4 shared publications- Daniel R. Morales
Population Health and Genomics Division, University of Dundee, Dundee, UK
4 shared publications Jim Slattery
Department of Pharmacovigilance and Epidemiology, European Medicines Agency, London, United Kingdom
4 shared publicationsXavier Kurz
Department of Pharmacovigilance and Epidemiology, European Medicines Agency, London, United Kingdom
4 shared publicationsPeter Arlett
European Medicines Agency Amsterdam The Netherlands
3 shared publicationsAbigail Robinson
Medical Sciences Division University of Oxford Oxford UK
2 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Regulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance
Regulatory bodies play a central role in providing guidance that enables safe and effective use of artificial intelligence tools in medicine development and evaluation. Regulators can also act as catalysts for regulatory science research. To inform these efforts, a European‐wide survey was conducted to solicit stakeholder perspectives on the priority areas for regulatory science research related to the use of artificial intelligence in the medicine lifecycle. Twenty‐eight regulatory science research questions were developed covering seven thematic domains: (1) research integrity and intellectual property; (2) accuracy and reliability of AI tools; (3) data governance, confidentiality, and consent; (4) regulation and oversight; (5) ethics, fairness, and bias prevention; (6) resources and support for AI use; and (7) impact on jobs and skills. Within each domain, stakeholders ranked four research challenges. A total of 273 responses were collected from regulators, pharmaceutical industry professionals, patients and consumers, academics, and healthcare professionals. Rankings of research challenges frequently converged across stakeholder groups and levels of AI experience. The top‐ranked research questions within each domain were weighted according to the overall importance ranking of each domain to identify a list of 10 priority areas of research. The majority of the 10 priority areas fell within the domains of “Accuracy and reliability of AI tools,” “Data governance, confidentiality, and consent,” and “Ethics, fairness, and bias prevention.” This list aims to support researchers and research funding bodies in addressing knowledge gaps on artificial intelligence in the medicines lifecycle.
- 13 August 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Open AccessRegulatory Research Priorities for AI Use in the Medicine Lifecycle: A European Perspective with Global Relevance
Regulatory bodies play a central role in providing guidance that enables safe and effective use of artificial intelligence tools in medicine development and evaluation. Regulators can also act as catalysts for regulatory science research. To inform these efforts, a European‐wide survey was conducted to solicit stakeholder perspectives on the priority areas for regulatory science research related to the use of artificial intelligence in the medicine lifecycle. Twenty‐eight regulatory science research questions were developed covering seven thematic domains: (1) research integrity and intellectual property; (2) accuracy and reliability of AI tools; (3) data governance, confidentiality, and consent; (4) regulation and oversight; (5) ethics, fairness, and bias prevention; (6) resources and support for AI use; and (7) impact on jobs and skills. Within each domain, stakeholders ranked four research challenges. A total of 273 responses were collected from regulators, pharmaceutical industry professionals, patients and consumers, academics, and healthcare professionals. Rankings of research challenges frequently converged across stakeholder groups and levels of AI experience. The top‐ranked research questions within each domain were weighted according to the overall importance ranking of each domain to identify a list of 10 priority areas of research. The majority of the 10 priority areas fell within the domains of “Accuracy and reliability of AI tools,” “Data governance, confidentiality, and consent,” and “Ethics, fairness, and bias prevention.” This list aims to support researchers and research funding bodies in addressing knowledge gaps on artificial intelligence in the medicines lifecycle.
- Open Access
- 22 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 335-336
Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health
- 22 November 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (2) , 335-336
Open AccessArtificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health
- Open Access
- 12 November 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (11) , e70042
Standardised and Reproducible Phenotyping Using Distributed Analytics and Tools in the Data Analysis and Real World Interrogation Network (DARWIN EU)
Purpose: The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework for reliable and traceable phenotype generation based on real world data for use in the Data Analysis and Real‐World Interrogation Network (DARWIN EU). We illustrate the use of this framework by generating phenotypes for two diseases: pancreatic cancer and systemic lupus erythematosus (SLE).Methods: The phenotyping process involves a 14‐steps process based on a standard operating procedure co‐created by the DARWIN EU Coordination Centre in collaboration with the European Medicines Agency. A number of bespoke R packages were utilised to generate and review codelists for two phenotypes based on real world data mapped to the OMOP Common Data Model.Results: Codelists were generated for both pancreatic cancer and SLE, and cohorts were generated in six OMOP‐mapped databases. Diagnostic checks were performed, which showed these cohorts had broadly similar incidence and prevalence figures to previously published literature, despite significant inter‐database variability. Co‐occurrent symptoms, conditions, and medication use were in keeping with pre‐specified clinical descriptions based on previous knowledge.Conclusions: Our detailed phenotyping process makes use of bespoke tools and allows for comprehensive codelist generation and review, as well as large‐scale exploration of the characteristics of the resulting cohorts. Wider use of structured and reproducible phenotyping methods will be important in ensuring the reliability of observational studies for regulatory purposes.
- 12 November 2024
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 33 (11) , e70042
Open AccessStandardised and Reproducible Phenotyping Using Distributed Analytics and Tools in the Data Analysis and Real World Interrogation Network (DARWIN EU)
Purpose: The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework for reliable and traceable phenotype generation based on real world data for use in the Data Analysis and Real‐World Interrogation Network (DARWIN EU). We illustrate the use of this framework by generating phenotypes for two diseases: pancreatic cancer and systemic lupus erythematosus (SLE).Methods: The phenotyping process involves a 14‐steps process based on a standard operating procedure co‐created by the DARWIN EU Coordination Centre in collaboration with the European Medicines Agency. A number of bespoke R packages were utilised to generate and review codelists for two phenotypes based on real world data mapped to the OMOP Common Data Model.Results: Codelists were generated for both pancreatic cancer and SLE, and cohorts were generated in six OMOP‐mapped databases. Diagnostic checks were performed, which showed these cohorts had broadly similar incidence and prevalence figures to previously published literature, despite significant inter‐database variability. Co‐occurrent symptoms, conditions, and medication use were in keeping with pre‐specified clinical descriptions based on previous knowledge.Conclusions: Our detailed phenotyping process makes use of bespoke tools and allows for comprehensive codelist generation and review, as well as large‐scale exploration of the characteristics of the resulting cohorts. Wider use of structured and reproducible phenotyping methods will be important in ensuring the reliability of observational studies for regulatory purposes.
- Open Access
- 11 April 2024
- Published by Wiley
Standardised and reproducible phenotyping using distributed analytics and tools in the Data Analysis and Real World Interrogation Network (DARWIN EU®)
Purpose The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework for reliable and traceable phenotype generation based on real world data for use in the Data Analysis and Real-World Interrogation Network (DARWIN EU®). We illustrate the use of this framework by generating phenotypes for two complex diseases: pancreatic cancer and systemic lupus erythematosus (SLE). Methods The phenotyping process involves a 14-step process based on a standard operating procedure co-created by the DARWIN EU® Coordination Centre in collaboration with the European Medicines Agency. A number of bespoke R packages were utilised to generate and review codelists for two phenotypes based on real world data mapped to the OMOP Common Data Model. Results Phenotypes were generated for both pancreatic cancer and SLE, and cohorts were generated using the Clinical Practice Research Datalink (UK primary care records) and Pharmetrics (US health claims data). Diagnostic checks were performed, which showed these cohorts had broadly similar incidence and prevalence figures to previously published literature. Additionally, co-occurrent symptoms, conditions, and medication use were in keeping with pre-specified clinical descriptions based on previous knowledge. Conclusions Our detailed phenotyping process makes use of bespoke tools and allows for comprehensive codelist generation and review, as well as large-scale exploration of the characteristics of the generated cohorts. Wider use of structured phenotyping methods will be important in ensuring the reliability of observational studies for regulatory purposes.
- 11 April 2024
- Published by Wiley
Open AccessStandardised and reproducible phenotyping using distributed analytics and tools in the Data Analysis and Real World Interrogation Network (DARWIN EU®)
Purpose The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework for reliable and traceable phenotype generation based on real world data for use in the Data Analysis and Real-World Interrogation Network (DARWIN EU®). We illustrate the use of this framework by generating phenotypes for two complex diseases: pancreatic cancer and systemic lupus erythematosus (SLE). Methods The phenotyping process involves a 14-step process based on a standard operating procedure co-created by the DARWIN EU® Coordination Centre in collaboration with the European Medicines Agency. A number of bespoke R packages were utilised to generate and review codelists for two phenotypes based on real world data mapped to the OMOP Common Data Model. Results Phenotypes were generated for both pancreatic cancer and SLE, and cohorts were generated using the Clinical Practice Research Datalink (UK primary care records) and Pharmetrics (US health claims data). Diagnostic checks were performed, which showed these cohorts had broadly similar incidence and prevalence figures to previously published literature. Additionally, co-occurrent symptoms, conditions, and medication use were in keeping with pre-specified clinical descriptions based on previous knowledge. Conclusions Our detailed phenotyping process makes use of bespoke tools and allows for comprehensive codelist generation and review, as well as large-scale exploration of the characteristics of the generated cohorts. Wider use of structured phenotyping methods will be important in ensuring the reliability of observational studies for regulatory purposes.
- 8 September 2022
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 31 (12) , 1308-1310
Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability
- 8 September 2022
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 31 (12) , 1308-1310
Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability
- Open Access
- 26 September 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1311-1317
Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
The relevance of biological therapies for an increasing number of conditions is on the rise. Following the expiry of the initial period of market exclusivity, many of these successful therapies have seen the arrival of biosimilars on the market. The clear identification of the precise medicine responsible for an adverse drug reaction (ADR) report is an important element for pharmacovigilance, allowing timely detection of potential product-specific safety signals. We looked at the identifiability of biologicals up to the level of commercial product name in ADR reports received from European clinical practice between 2011 and December 2019. A good level of identification (91.5%) was observed overall, but at the same time a downward trend was observed in the last 5 years. This reduction in the level of identifiability of biological products (originators and biosimilars) at the commercial name level in general was driven by 5 widely used substances, while the identification of all other biologics stayed consistent over time (at over 90%). We observed that those 5 substances were used mostly within oncology. The introduction of the first biosimilar in the market did not appear to affect their identifiability. These results show that although the general level of identification at the commercial product name level in ADRs in Europe is robust and generally stable over time, decreasing trends can be down to a few commonly used substances which need to be monitored to reverse the trend.
- 26 September 2021
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1311-1317
Open AccessIdentifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions
The relevance of biological therapies for an increasing number of conditions is on the rise. Following the expiry of the initial period of market exclusivity, many of these successful therapies have seen the arrival of biosimilars on the market. The clear identification of the precise medicine responsible for an adverse drug reaction (ADR) report is an important element for pharmacovigilance, allowing timely detection of potential product-specific safety signals. We looked at the identifiability of biologicals up to the level of commercial product name in ADR reports received from European clinical practice between 2011 and December 2019. A good level of identification (91.5%) was observed overall, but at the same time a downward trend was observed in the last 5 years. This reduction in the level of identifiability of biological products (originators and biosimilars) at the commercial name level in general was driven by 5 widely used substances, while the identification of all other biologics stayed consistent over time (at over 90%). We observed that those 5 substances were used mostly within oncology. The introduction of the first biosimilar in the market did not appear to affect their identifiability. These results show that although the general level of identification at the commercial product name level in ADRs in Europe is robust and generally stable over time, decreasing trends can be down to a few commonly used substances which need to be monitored to reverse the trend.
- Open Access
- 19 January 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 944-947
An Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity
Dihydropyrimidine dehydrogenase (DPD)‐deficient patients might only become aware of their genotype after exposure to dihydropyrimidines, if testing is performed. Case reports to pharmacovigilance databases might only contain phenotypical manifestations of DPD, without information on the genotype. This poses a difficulty in estimating the cases due to DPD. Auto machine learning models were developed to train patterns of phenotypical manifestations of toxicity, which were then used as a surrogate to estimate the number of cases of DPD‐related toxicity. Results indicate that between 8,878 (7.0%) and 16,549 (13.1%) patients have a profile similar to DPD deficient status. Results of the analysis of variable importance match the known end‐organ damage of DPD‐related toxicity, however, accuracies in the range of 90% suggest presence of overfitting, thus, results need to be interpreted carefully. This study shows the potential for use of machine learning in the regulatory context but additional studies are required to better understand regulatory applicability.
- 19 January 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 944-947
Open AccessAn Application of Machine Learning in Pharmacovigilance: Estimating Likely Patient Genotype From Phenotypical Manifestations of Fluoropyrimidine Toxicity
Dihydropyrimidine dehydrogenase (DPD)‐deficient patients might only become aware of their genotype after exposure to dihydropyrimidines, if testing is performed. Case reports to pharmacovigilance databases might only contain phenotypical manifestations of DPD, without information on the genotype. This poses a difficulty in estimating the cases due to DPD. Auto machine learning models were developed to train patterns of phenotypical manifestations of toxicity, which were then used as a surrogate to estimate the number of cases of DPD‐related toxicity. Results indicate that between 8,878 (7.0%) and 16,549 (13.1%) patients have a profile similar to DPD deficient status. Results of the analysis of variable importance match the known end‐organ damage of DPD‐related toxicity, however, accuracies in the range of 90% suggest presence of overfitting, thus, results need to be interpreted carefully. This study shows the potential for use of machine learning in the regulatory context but additional studies are required to better understand regulatory applicability.
- 1 July 2019
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 76 (7) , 827-833
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy
Importance Peripheral neuropathy has been associated with systemic fluoroquinolone exposure, but risk has been poorly quantified. Objective To calculate relative and absolute risk estimates for the association of fluoroquinolone exposure with peripheral neuropathy and to examine how risk may be affected by timing of fluoroquinolone exposure and by other risk factors. Design, Setting, and Participants This nested case-control study used anonymized data from all patients routinely registered with general practices in The Health Improvement Network database, a large primary care population database in the United Kingdom, from January 1, 1999, to December 31, 2015. Data analyses were conducted January 8, 2018. The cohort consisted of 1 338 900 adults issued 1 or more prescriptions of fluoroquinolone (34.3%) or amoxicillin-clavulanate (65.7%) antibiotics. Adults with incident peripheral neuropathy were matched (on age, sex, general practice, and calendar time) with up to 4 controls by using incidence density sampling selected from a cohort prescribed oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Incidence rate ratios of peripheral neuropathy were calculated for fluoroquinolone and for amoxicillin-clavulanate exposure and compared with nonexposure among patients without diabetes, with sensitivity analyses testing the consistency of the results. Population mean–adjusted rate differences were then estimated, including the number needed to harm for various durations of fluoroquinolone therapy. Exposures Current and cumulative exposure to oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Main Outcomes and Measures Incident peripheral neuropathy cases recorded in electronic medical records. Results In total, 5357 patients with incident peripheral neuropathy (mean [SD] age, 65.6 [14.7] years; 2809 women [52.4%]) were matched to 17 285 controls (mean [SD] age, 64.4 [15.2] years; 9485 women [54.9%]) without diabetes. Current oral fluoroquinolone exposure was associated with an increased relative incidence of peripheral neuropathy compared with nonexposure (adjusted incident rate ratio, 1.47; 95% CI, 1.13-1.92). Risk increased by approximately 3% for each additional day of current fluoroquinolone exposure and persisted for up to 180 days following exposure. No significant increased risk was observed with oral amoxicillin-clavulanate exposure. The absolute risk with current oral fluoroquinolone exposure was 2.4 (95% CI, 1.8-3.1) per 10 000 patients per year of current use. The number needed to harm for a 10-day course was 152 083 patients (95% CI, 117 742-202 778) and was greatest among men and among patients older than 60 years. Conclusions and Relevance The results of the present study suggested that oral fluoroquinolone therapy was associated with an increased risk of incident peripheral neuropathy that may depend on the timing of the exposure and the cumulative dose. Health care professionals should consider these potential risks when prescribing fluoroquinolone antibiotics.
- 1 July 2019
- Published by American Medical Association (AMA) in JAMA Neurology
- Vol. 76 (7) , 827-833
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy
Importance Peripheral neuropathy has been associated with systemic fluoroquinolone exposure, but risk has been poorly quantified. Objective To calculate relative and absolute risk estimates for the association of fluoroquinolone exposure with peripheral neuropathy and to examine how risk may be affected by timing of fluoroquinolone exposure and by other risk factors. Design, Setting, and Participants This nested case-control study used anonymized data from all patients routinely registered with general practices in The Health Improvement Network database, a large primary care population database in the United Kingdom, from January 1, 1999, to December 31, 2015. Data analyses were conducted January 8, 2018. The cohort consisted of 1 338 900 adults issued 1 or more prescriptions of fluoroquinolone (34.3%) or amoxicillin-clavulanate (65.7%) antibiotics. Adults with incident peripheral neuropathy were matched (on age, sex, general practice, and calendar time) with up to 4 controls by using incidence density sampling selected from a cohort prescribed oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Incidence rate ratios of peripheral neuropathy were calculated for fluoroquinolone and for amoxicillin-clavulanate exposure and compared with nonexposure among patients without diabetes, with sensitivity analyses testing the consistency of the results. Population mean–adjusted rate differences were then estimated, including the number needed to harm for various durations of fluoroquinolone therapy. Exposures Current and cumulative exposure to oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Main Outcomes and Measures Incident peripheral neuropathy cases recorded in electronic medical records. Results In total, 5357 patients with incident peripheral neuropathy (mean [SD] age, 65.6 [14.7] years; 2809 women [52.4%]) were matched to 17 285 controls (mean [SD] age, 64.4 [15.2] years; 9485 women [54.9%]) without diabetes. Current oral fluoroquinolone exposure was associated with an increased relative incidence of peripheral neuropathy compared with nonexposure (adjusted incident rate ratio, 1.47; 95% CI, 1.13-1.92). Risk increased by approximately 3% for each additional day of current fluoroquinolone exposure and persisted for up to 180 days following exposure. No significant increased risk was observed with oral amoxicillin-clavulanate exposure. The absolute risk with current oral fluoroquinolone exposure was 2.4 (95% CI, 1.8-3.1) per 10 000 patients per year of current use. The number needed to harm for a 10-day course was 152 083 patients (95% CI, 117 742-202 778) and was greatest among men and among patients older than 60 years. Conclusions and Relevance The results of the present study suggested that oral fluoroquinolone therapy was associated with an increased risk of incident peripheral neuropathy that may depend on the timing of the exposure and the cumulative dose. Health care professionals should consider these potential risks when prescribing fluoroquinolone antibiotics.
- Open Access
- 21 November 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 39 (2) , 205-213
Relative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study
Background and Objective Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing of exposure. Methods The UK Health Improvement Network primary care database was used to perform a nested case–control study measuring the association between fluoroquinolone exposure and tendon rupture. Adults with tendon rupture were matched on age, sex, general practice and calendar time to four controls selected from a cohort prescribed systemic fluoroquinolone or co-amoxiclav antibiotics. The relative and absolute risk of tendon rupture with fluoroquinolone exposure was calculated. Results Current fluoroquinolone exposure was associated with an increased risk of any tendon rupture (adjusted incidence rate ratio [aIRR] 1.61, 95% CI 1.25–2.09) and Achilles tendon rupture (aIRR 3.14, 95% CI 2.11–4.65) that persisted for 60 days. Risk increased with cumulative exposure and was greatest when co-prescribed with oral corticosteroids (aIRR 19.36, 95% CI 7.78–48.19 for Achilles tendon rupture). The adjusted rate difference (aRD) with fluoroquinolone exposure was 2.9 and 2.1 per 10,000 patients for any and Achilles tendon rupture, respectively, and was greatest in people aged ≥ 60 years prescribed concomitant oral corticosteroid therapy (aDR 19.6 for any tendon and 6.6 Achilles tendon rupture per 10,000). No association was seen with co-amoxiclav or statin exposure, or with biceps or other tendon ruptures. Conclusions Risk of tendon rupture with fluoroquinolones depends on timing, cumulative dose and concomitant exposure to oral corticosteroids. Absolute risk significantly varied by age and concomitant corticosteroid exposure, affecting elderly patients the greatest.
- 21 November 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 39 (2) , 205-213
Open AccessRelative and Absolute Risk of Tendon Rupture with Fluoroquinolone and Concomitant Fluoroquinolone/Corticosteroid Therapy: Population-Based Nested Case–Control Study
Background and Objective Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing of exposure. Methods The UK Health Improvement Network primary care database was used to perform a nested case–control study measuring the association between fluoroquinolone exposure and tendon rupture. Adults with tendon rupture were matched on age, sex, general practice and calendar time to four controls selected from a cohort prescribed systemic fluoroquinolone or co-amoxiclav antibiotics. The relative and absolute risk of tendon rupture with fluoroquinolone exposure was calculated. Results Current fluoroquinolone exposure was associated with an increased risk of any tendon rupture (adjusted incidence rate ratio [aIRR] 1.61, 95% CI 1.25–2.09) and Achilles tendon rupture (aIRR 3.14, 95% CI 2.11–4.65) that persisted for 60 days. Risk increased with cumulative exposure and was greatest when co-prescribed with oral corticosteroids (aIRR 19.36, 95% CI 7.78–48.19 for Achilles tendon rupture). The adjusted rate difference (aRD) with fluoroquinolone exposure was 2.9 and 2.1 per 10,000 patients for any and Achilles tendon rupture, respectively, and was greatest in people aged ≥ 60 years prescribed concomitant oral corticosteroid therapy (aDR 19.6 for any tendon and 6.6 Achilles tendon rupture per 10,000). No association was seen with co-amoxiclav or statin exposure, or with biceps or other tendon ruptures. Conclusions Risk of tendon rupture with fluoroquinolones depends on timing, cumulative dose and concomitant exposure to oral corticosteroids. Absolute risk significantly varied by age and concomitant corticosteroid exposure, affecting elderly patients the greatest.
- 24 August 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (10) , 927-933
Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study
- 24 August 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (10) , 927-933
Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study